Page 6 - Recurrence Score News Today

In the study, postmenopausal women with 1 to 3 positive nodes and Recurrence Score® results of 0 to 25 showed no benefit from chemotherapy after a median of five years of follow-up, meaning they can potentially avoid negative side effects of the treatment. - Click here if this is your press release! - eTurboNews | Trends | Travel News

- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women -

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER,...

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER,...

/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September...

/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japans Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX...

Exact Sciences Announces Fourth Quarter 2020 Results News provided by Share this article Share this article MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. "Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because...

Genomic test has lower prognostic accuracy in minority patients with breast cancer Black women have higher recurrence and mortality rates than non-Hispanic white women for certain types of breast cancer, according to a University of Illinois Chicago researchers study published recently in JAMA Oncology. Dr. Kent Hoskins, associate professor in the UIC College of Medicines division of hematology/oncology, and co-leader of the Breast Cancer Research group in the University of Illinois Cancer Cen...

0 to 10: HR 2.54 (95% CI 1.44-4.50) 11 to 25: HR 1.64 (95% CI 1.23-2.18) >25: HR 1.48 (95% CI 1.10-1.98) "This study suggests that Black women in the U.S. with ER-positive, ERBB2-negative, axillary lymph node-negative breast cancer are more likely to have a high-risk RS [recurrence score] and to experience breast cancer-specific mortality compared with non-Hispanic white women within the same risk group," Hoskins and co-authors wrote. "In addition, the RS provides less prognostic information f...

 E-Mail Black women have higher recurrence and mortality rates than non-Hispanic white women for certain types of breast cancer, according to a University of Illinois Chicago researchers study published recently in JAMA Oncology. Dr. Kent Hoskins, associate professor in the UIC College of Medicines division of hematology/oncology, and co-leader of the Breast Cancer Research group in the University of Illinois Cancer Center, published the study, "Association of race/ethnicity and the 21-gene ...